



By late fall 2010, the University of Saskatchewan (U of S) will be home to the \$140-million International Vaccine Centre (InterVac), one of the largest Containment Level 3 (CL3) vaccine research and development facilities in North America. InterVac will be located at the Vaccine and Infectious Disease Organization (VIDO).

> A MESSAGE TO OUR PARTNERS IN INDUSTRY:

"The Vaccine Infectious Disease Organization (VIDO) began operating at the University of Saskatchewan in 1975, and our experience in providing an exceptional user services program is un-matched in North America. Although we have achieved tremendous success in developing new vaccines, our ability to respond to emerging diseases quickly was hampered by the lack of a facility in which to effectively test vaccines.

"That gap is closing. VIDO will soon be home to the International Vaccine Centre, or InterVac. This unique facility provides VIDO with technologies and capabilities to study a greater number of diseases, including Containment Level 3 (CL3) diseases, develop new vaccines, and appropriately test them. We can now work with you to get these vaccines to market more quickly so that they are available when they are needed most."

– Dr. Andrew Potter, Director, VIDO-InterVac

Our number one goal is to develop, test and get vaccines to the user much sooner than ever before

Your investment in VIDO-InterVac allows us to address more of the difficult animal and human health challenges, and anticipate new threats as they emerge.

Together with VIDO, InterVac offers an innovative approach to research and development

A state-of-the-art, \$140-million facility with 145,000 square feet of space and a distinctive design, allows for a range of experiments from pre-clinical testing to licensing trials.

Capable of testing vaccines on all animal species

The CL3 capabilities of InterVac helps us to better understand the infectious disease interaction between humans and animals, and meet the growing need for animal and human vaccine research.

CL3 diseases

Examples of diseases that can be examined at InterVac include:

- Tuberculosis
- Influenza (including swine and avian influenza)
- Hantavirus
- HIV/AIDS
- BSE (Mad Cow disease)
- Chronic wasting disease
- Creutzfeldt-Jakob Disease
- SARS
- Rabies
- West Nile virus
- Hepatitis C

SOME VIDO HIGHLIGHTS

- VIDO is competitive nationally and internationally, with more than 80 awarded U.S. patents.
- VIDO has commercialized eight vaccines, six of which were world firsts.
- VIDO employs more than 150 people, and is the headquarters of the Pan-Provincial Vaccine Enterprise (PREVENT), one of Canada's new Centres of Excellence in commercialization and research.
- VIDO is a non-profit entity working to accelerate the rate at which vaccines are available to the public.
- VIDO has received millions of research dollars from organizations such as the Gates and Krembil Foundations and agencies such as the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, Genome Canada, National Institutes of Health, and others.

Users of VIDO-InterVac are provided with:

Opportunities for Collaboration

InterVac is open to academic teams and researchers from Canadian and international universities, commercial partners, research institutes and governments. The facility operates with the best interests of industry in mind, ultimately working together to serve people around the world, not only because of its physical design, but because of the opportunities it allows for collaboration. Opportunities for these types of collaboration in the vaccine field are unavailable elsewhere in North America.

Rapid Response

InterVac will enable researchers to gain deeper understanding of CL3 diseases and respond faster to emerging diseases affecting animals and humans. This will help commercial partners such as biopharmaceutical companies bring their products to market faster, helping Canadians and people worldwide.

A Unique Cluster of Life Sciences R&D

VIDO-InterVac is part of the dynamic research and bioscience cluster that exists on the University of Saskatchewan campus and includes:

- Colleges of medicine, nursing, pharmacy and nutrition, the Western College of Veterinary Medicine, and the School of Public Health;
- The University's research park, Innovation Place, one of the most successful in North America in developing new ideas in fields ranging from agricultural biotechnology and pharmaceutical development, to advanced communications and information technology; and
- The Canadian Light Source, the country's only synchrotron.

Protecting animals, saving lives

Our goal is to address the world's most challenging diseases and suppress future epidemics by bringing effective vaccines to market quickly. We can only achieve this goal through partner support. As construction on InterVac continues, VIDO is now working to secure on-going operational funding in the amount of \$25 million per year.

We all have a role to play in ensuring that worldwide pandemics, diseases and viruses are mitigated and eliminated. InterVac will help ensure we rise to that challenge. Through innovation, and the combined efforts of our partners in industry, academia and government, we are pursuing our vision of anticipating, responding to, and changing the face of infectious disease on our planet.

"Research centres like VIDO-InterVac are placing the University of Saskatchewan among the leading universities in the country. InterVac, the Canadian Light Source, and our unique array of life science programs are establishing a global reputation for the U of S, attracting top faculty and students to the campus."

President Peter MacKinnon
University of Saskatchewan



For more information about VIDO or InterVac, please visit www.vido.org or contact us at:

VIDO-InterVac

120 Veterinary Road, Saskatoon, SK S7N 5E3
Phone (306) 966-7465 Fax (306) 966-7478

